Intracranial Activity of Cabozantinib in MET Exon 14–Positive NSCLC with Brain Metastases
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2016.09.127
Abstract: Introduction: A significant portion of NSCLCs with MET proto‐oncogene, receptor tyrosine kinase gene (MET) exon 14 skipping alterations are sensitive to small‐molecule mesenchymal‐epithelial transition tyrosine kinase inhibitors. However, the incidence and management of brain metastases… read more here.
Keywords: brain metastases; positive nsclc; exon positive; cabozantinib ... See more keywords
Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.08.009
Abstract: BACKGROUND Most studies on MET exon 14 (MET-ex14) alteration, defined as an oncogenic driver, have been carried out among Caucasians; similar studies among Chinese people are limited. METHODS We retrospectively analyzed the genomic profiles of… read more here.
Keywords: versus months; met ex14; clinical outcomes; months versus ... See more keywords
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-19-3608
Abstract: Purpose: Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors (TKI) are poorly understood. We aimed to characterize the genomic mechanisms of resistance to type I and type II MET TKIs and their impact… read more here.
Keywords: molecular mechanisms; met exon; resistance met; mechanisms resistance ... See more keywords
Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience
Sign Up to like & getrecommendations! Published in 2022 at "Oncology"
DOI: 10.1159/000525188
Abstract: Introduction: Non-small cell lung cancer (NSCLC) accounts for most lung cancers and is a leading cause of cancer-related deaths in the USA. Alterations in c-MET, a tyrosine kinase receptor, have been involved in many cases… read more here.
Keywords: lung cancer; crizotinib; met exon; mutation ... See more keywords
Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer.
Sign Up to like & getrecommendations! Published in 2022 at "Clinical journal of oncology nursing"
DOI: 10.1188/22.cjon.543-551
Abstract: BACKGROUND Tepotinib, a highly selective, oral, once-daily MET inhibitor, has been approved for treatment of metastatic MET exon 14 skipping non-small cell lung cancer. OBJECTIVES This article provides nurse-specific recommendations for identification and management of… read more here.
Keywords: non small; skipping non; small cell; met exon ... See more keywords
Coexistence of MET exon 14 mutations with EGFR mutations in non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20636
Abstract: e20636Background: Activation of MET oncogene as the result of amplification or activation MET exon 14 mutations represents an emerging molecular target for non-small cell lung cancer (NSCLC) treatm... read more here.
Keywords: exon mutations; lung cancer; cell lung; non small ... See more keywords
Identification of MET Exon 14 skipping by targeted RNA-based next-generation sequencing in Chinese Patients with NSCLC.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.e20018
Abstract: e20018 Background: MET (mesenchymal-epithelial transition) exon14 skipping mutations have been reported to represent a clinically unique molecular subtype of NSCLC. The prevalence rates of MET exon 14 skipping in lung adenocarcinoma are quite different, from… read more here.
Keywords: met exon; based next; nsclc patients; next generation ... See more keywords
Characterization of 1,387 NSCLCs with MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance (AR) mechanisms.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.9511
Abstract: 9511Background: METex14 SA are oncogenic drivers in NSCLC. Due to the numerous sites around ex14 that bind the spliceosome complex, many variations can result in deleterious alterations (alts). We ... read more here.
Keywords: nsclcs met; exon metex14; characterization 387; metex14 ... See more keywords
Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+).
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2020.38.15_suppl.9519
Abstract: 9519Background: There are unmet medical needs for pts with METex14+ NSCLC. PSC is a rare type of NSCLC with high incidence of MET exon 14 mutations and poor prognosis. Savolitinib (AZD6094, HMPL-50... read more here.
Keywords: psc; savolitinib patients; patients pts; study savolitinib ... See more keywords
Frequency of MET exon 14 skipping mutations in non-small cell lung cancer according to technical approach in routine diagnosis: results from a real-life cohort of 2,369 patients.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of thoracic disease"
DOI: 10.21037/jtd.2020.04.21
Abstract: Background Mesenchymal epithelial transition receptor (MET) alterations, including MET exon 14 skipping mutation, are oncogenic in non-small cell lung cancer (NSCLC) and may confer sensitivity to targeted therapy. Given the rarity and the diversity of… read more here.
Keywords: skipping mutations; small cell; cell lung; non small ... See more keywords
Spotlight on Tepotinib and Capmatinib for Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutation
Sign Up to like & getrecommendations! Published in 2022 at "Lung Cancer: Targets and Therapy"
DOI: 10.2147/lctt.s360574
Abstract: Abstract Mesenchymal-epithelial transition (MET) receptor tyrosine kinase is overexpressed, amplified, or mutated in 1–20% of NSCLC. MET dysregulation is associated with a poor prognosis. Recently, development of targeted therapies against MET exon 14 mutations has… read more here.
Keywords: tepotinib capmatinib; met exon; lung cancer;